文献速递贫血与红细胞疾病

羟基脲治疗镰状细胞贫血儿童临床诊断感染发生率:REACH试验回顾性队列研究

Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial.
PubMed 文献 · Lancet Haematol · 2026-10-07

REACH试验在安哥拉、刚果民主共和国、肯尼亚和乌干达四家医院纳入606名1-10岁镰状细胞贫血儿童,分析羟基脲治疗各阶段临床诊断感染的发生率。

要点

  • 羟基脲治疗未增加镰状细胞贫血患儿感染发生率和严重程度。
  • 上呼吸道、下呼吸道、细菌性皮肤/甲感染及非特异性感染综合征发生率均随治疗阶段下降。

核心结论

  • 在REACH大型队列中,撒哈拉以南非洲镰状细胞贫血儿童接受羟基脲治疗各阶段,临床诊断感染的发生率或严重程度未增加。
  • 即使使用最大耐受剂量,羟基脲也不增加感染致病或死亡风险。

研究设计与样本

  • REACH为正在进行的1/2期开放标签多中心治疗试验(NCT01966731和NCT06171217)。
  • 本次国际回顾性队列研究纳入安哥拉、刚果民主共和国、肯尼亚和乌干达四家医院招募的1-10岁镰状细胞贫血儿童。
  • 606名儿童完成筛查并开始羟基脲治疗(296名女性,310名男性)。

临床怎么用

  • 羟基脲治疗镰状细胞贫血患儿时,无需因担忧感染风险而限制其使用或剂量递增至最大耐受剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hydroxyurea is widely used in the first-line treatment of sickle cell anaemia; however, its mildly myelosuppressive effects when used at therapeutic doses have led to suggestions that treatment with hydroxyurea might increase the risk of infection. To address this question, we have investigated the incidence of clinically diagnosed infections among children within the Realizing Effectiveness Across Continents with Hydroxyurea (REACH) trial during various phases of hydroxyurea treatment. METHODS: REACH (NCT01966731 and NCT06171217) is an ongoing, phase 1/2, open-label, multicentre treatment trial of children with sickle cell anaemia with 2 months of screening followed by oral hydroxyurea at a fixed dose for 6 months and then dose escalation to the maximum tolerated dose (MTD). The current international, retrospective cohort study included children aged 1-10 years with sickle cell anaemia who were recruited and enrolled into REACH from four hospitals in Angola, DR Congo, Kenya, and Uganda and who had previously been followed up within the trial. Clinically diagnosed infections were characterised by likely aetiology and severity and incidence rate ratios (IRR) were then computed across time and during dosing phases as protocol-specified outcomes. The primary outcome of the current analysis was the incidence of clinically diagnosed infections, which was stratified by hydroxyurea treatment phase and assessed in all children who started fixed-dose hydroxyurea treatment. Rates of each clinically diagnosed infection (per 100 person-years of observation [PYO]) were calculated by age group and dosing phase. FINDINGS: Between July 4, 2014, and Nov 11, 2016, 635 children were enrolled in the trial. 606 children (296 [49%] female and 310 [51%] male) completed screening and began treatment with hydroxyurea. Overall, 5493 infections occurred across 5638 PYO, with an incidence rate of 97·4/100 PYO. Among non-malarial infections, rates declined from the screening to fixed-dose phase (adjusted IRR 0·81 [95% CI 0·67-0·98]) and decreased further from the screening to the MTD phase (0·51 [0·43-0·61]; p<0·0001). Statistically significant decreases across the fixed-dose, dose-escalation, and MTD phases, respectively, were observed in the adjusted IRRs for upper respiratory tract infections (IRR 0·84 [95% CI 0·62-1·14], 0·77 [0·58-1·03], and 0·64 [0·47-0·88]; p=0·0051), lower respiratory tract infections (1·26 [0·69-2·31], 0·60 [0·32-1·12], and 0·45 [0·23-0·89]; p=0·021), bacterial skin or nail infections (0·58 [0·26-1·30], 0·32 [0·15-0·68], and 0·31 [0·14-0·66]; p=0·0025), and non-specific infectious syndromes (0·80 [0·58-1·11], 0·47 [0·35-0·63], and 0·39 [0·28-0·53]; p<0·0001). A similar decrease was observed for the adjusted IRR of grade 3 or higher infections across the fixed-dose, dose-escalation, and MTD phases, respectively (0·65 [0·42-1·00], 0·20 [0·13-0·32], and 0·48 [0·32-0·73]; p=0·0006). INTERPRETATION: In the large REACH cohort, the incidence rate or severity of clinically diagnosed infections in children with sickle cell anaemia living in sub-Saharan Africa, was not increased during the hydroxyurea treatment phases of this trial. Our results provide reassurance that, even when administered at MTD, hydroxyurea does not put children with sickle cell anaemia at increased risk of illness or death from infections. FUNDING: US National Heart, Lung, and Blood Institute. TRANSLATIONS: For the French, Portuguese and Swahili translations of the abstract see Supplementary Materials section.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Williams TN, Smart LR, Tomlinson G, et al. Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial. Lancet Haematol. 2026. PMID: 42843398. doi:10.1016/S2352-3026(26)00246-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。